Oppenheimer analyst Jay Olson maintained a Hold rating on Enanta Pharmaceuticals (ENTA) yesterday. The company’s shares closed yesterday at $99.66.
According to TipRanks.com, Olson has 0 stars on 0-5 star ranking scale with an average return of -2.8% and a 42.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Axovant Gene Therapies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Enanta Pharmaceuticals with a $101.67 average price target.
See today’s analyst top recommended stocks >>
Enanta Pharmaceuticals’ market cap is currently $1.94B and has a P/E ratio of 24.12. The company has a Price to Book ratio of 4.54.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENTA in relation to earlier this year. Earlier this month, Nathaniel Gardiner, the SVP & GC of ENTA bought 2,519 shares for a total of $84,802.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. Its brands include Mavyret and Viekira Pak.
